×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AZN – astrazeneca plc ordinary shares (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AZN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/3
07:55 pm
azn
Why Astrazeneca (AZN) Dipped More Than Broader Market Today [Yahoo! Finance]
Neutral
Report
Why Astrazeneca (AZN) Dipped More Than Broader Market Today [Yahoo! Finance]
2/3
07:22 pm
azn
Harbour BioMed Announces Positive Profit Alert for 2025 Annual Results [Yahoo! Finance]
Low
Report
Harbour BioMed Announces Positive Profit Alert for 2025 Annual Results [Yahoo! Finance]
2/3
12:02 pm
azn
Jim Cramer Says “I Like AstraZeneca Very Much” [Yahoo! Finance]
Low
Report
Jim Cramer Says “I Like AstraZeneca Very Much” [Yahoo! Finance]
2/3
10:56 am
azn
Walmart hits US$1 trillion in market value for the first time [BNN Bloomberg (Canada)]
Low
Report
Walmart hits US$1 trillion in market value for the first time [BNN Bloomberg (Canada)]
2/3
07:23 am
azn
DATROWAY® (datopotamab deruxtecan-dlnk) granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy [Yahoo! Finance]
Low
Report
DATROWAY® (datopotamab deruxtecan-dlnk) granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy [Yahoo! Finance]
2/3
07:00 am
azn
DATROWAY® (datopotamab deruxtecan-dlnk) granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy
Low
Report
DATROWAY® (datopotamab deruxtecan-dlnk) granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy
2/3
04:47 am
azn
AstraZeneca PLC (NASDAQ:AZN) Announces Strategic Collaboration Agreement With CSPC Pharmaceuticals [Yahoo! Finance]
Low
Report
AstraZeneca PLC (NASDAQ:AZN) Announces Strategic Collaboration Agreement With CSPC Pharmaceuticals [Yahoo! Finance]
2/3
02:53 am
azn
DATROWAY® Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy [Yahoo! Finance]
Low
Report
DATROWAY® Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/3
07:01 am
azn
Form 6-K ASTRAZENECA PLC For: Feb 03
Low
Report
Form 6-K ASTRAZENECA PLC For: Feb 03
2/2
01:27 pm
azn
Form 6-K ASTRAZENECA PLC For: Feb 02
Low
Report
Form 6-K ASTRAZENECA PLC For: Feb 02
2/2
07:52 am
azn
Form 6-K ASTRAZENECA PLC For: Feb 02
Low
Report
Form 6-K ASTRAZENECA PLC For: Feb 02
2/2
07:25 am
azn
Form 6-K ASTRAZENECA PLC For: Feb 02
Low
Report
Form 6-K ASTRAZENECA PLC For: Feb 02
1/30
06:19 am
azn
Form 6-K ASTRAZENECA PLC For: Jan 30
Low
Report
Form 6-K ASTRAZENECA PLC For: Jan 30
1/29
08:08 am
azn
Form 6-K ASTRAZENECA PLC For: Jan 29
Low
Report
Form 6-K ASTRAZENECA PLC For: Jan 29
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/17
AstraZeneca's combo lung cancer treatment fails late-stage study main goal [Reuters (UK)]
8.3%
4/9 Clovis Oncology Analyst Turns Bearish Ahead Of PDUFA Date For Rubraca [Yahoo! Finance News] 7.6%
3/3 Form 20-F ASTRAZENECA PLC For: Dec 31 6.8%
3/26 Form 6-K ASTRAZENECA PLC For: Mar 26 5.9%
10/24 AstraZeneca tops sales forecasts on China, new drug boosts [Reuters] 5.7%
7/25 AstraZeneca quarterly product sales beat on cancer drug strength [Reuters (UK)] 5.7%
3/30 Form 6-K ASTRAZENECA PLC For: Mar 30 5.5%
2/29 AstraZeneca plc (NYSE: AZN) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $55.00 price target on the stock. 4.5%
3/19 Form 6-K ASTRAZENECA PLC For: Mar 19 3.7%
4/14 AstraZeneca to test impact of cancer drug Calquence on coronavirus patients [Reuters] 2.9%
4/9 Clovis Oncology Analyst Turns Bearish Ahead Of PDUFA Date For Rubraca [Yahoo! Finance News] 7.6%
3/3 Form 20-F ASTRAZENECA PLC For: Dec 31 6.8%
3/26 Form 6-K ASTRAZENECA PLC For: Mar 26 5.9%
10/24 AstraZeneca tops sales forecasts on China, new drug boosts [Reuters] 5.7%
7/25 AstraZeneca quarterly product sales beat on cancer drug strength [Reuters (UK)] 5.7%
3/30 Form 6-K ASTRAZENECA PLC For: Mar 30 5.5%
2/29 AstraZeneca plc (NYSE: AZN) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $55.00 price target on the stock. 4.5%
3/19 Form 6-K ASTRAZENECA PLC For: Mar 19 3.7%
4/14 AstraZeneca to test impact of cancer drug Calquence on coronavirus patients [Reuters] 2.9%
TOP News Decliners
3/7
Amarin Stock Looks Like a Heart-Healthy Buy on the Dip [Yahoo! Finance News]
-4.1%
2/27 Form 6-K ASTRAZENECA PLC For: Feb 27 -3.9%
3/20 Form 6-K ASTRAZENECA PLC For: Mar 20 -3.5%
3/12 Form 6-K ASTRAZENECA PLC For: Mar 12 -2.9%
10/1 UPDATE 1-AstraZeneca's combo lung disease therapy fails to win FDA approval [Yahoo! Finance News] -2.7%
3/6 AstraZeneca's combo cancer treatment fails to meet late-stage study main goal [Reuters] -2.4%
12/30 AstraZeneca-Merck's Lynparza gets FDA okay to treat pancreatic cancer [Reuters] -2.3%
9/28 LYNPARZA (olaparib) Improved the Time Women Lived Without Disease Progression to 22 Months in the Broad Population and 37 Months in HRD-positive Patients as 1st-line Maintenance Treatment with Bevacizumab for Newly Diagnosed Advanced Ovarian Cancer -2.2%
10/1 AstraZeneca sells acid reflux drug rights to Germany's Cheplapharm [Reuters] -2.0%
8/14 LYNPARZA® (olaparib) Phase III Paola-1 Trial Met Primary Endpoint as 1st-line Maintenance Treatment With Bevacizumab for Advanced Ovarian Cancer -2.0%
2/27 Form 6-K ASTRAZENECA PLC For: Feb 27 -3.9%
3/20 Form 6-K ASTRAZENECA PLC For: Mar 20 -3.5%
3/12 Form 6-K ASTRAZENECA PLC For: Mar 12 -2.9%
10/1 UPDATE 1-AstraZeneca's combo lung disease therapy fails to win FDA approval [Yahoo! Finance News] -2.7%
3/6 AstraZeneca's combo cancer treatment fails to meet late-stage study main goal [Reuters] -2.4%
12/30 AstraZeneca-Merck's Lynparza gets FDA okay to treat pancreatic cancer [Reuters] -2.3%
9/28 LYNPARZA (olaparib) Improved the Time Women Lived Without Disease Progression to 22 Months in the Broad Population and 37 Months in HRD-positive Patients as 1st-line Maintenance Treatment with Bevacizumab for Newly Diagnosed Advanced Ovarian Cancer -2.2%
10/1 AstraZeneca sells acid reflux drug rights to Germany's Cheplapharm [Reuters] -2.0%
8/14 LYNPARZA® (olaparib) Phase III Paola-1 Trial Met Primary Endpoint as 1st-line Maintenance Treatment With Bevacizumab for Advanced Ovarian Cancer -2.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: